We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

21 hedge funds and large institutions have $2.15M invested in CASI Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

6.69% less ownership

Funds ownership: 13.67% → 6.98% (-6.7%)

9% less funds holding

Funds holding: 23 → 21 (-2)

35% less capital invested

Capital invested by funds: $3.29M → $2.15M (-$1.13M)

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
21
Holders Change
-2
Holders Change %
-8.7%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$9.15K
2
Northern Trust
Northern Trust
Illinois
+$8.15K
3
Renaissance Technologies
Renaissance Technologies
New York
+$4.24K
4
Franklin Resources
Franklin Resources
California
+$726

Top Sellers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
-$1.58M
2
WSCM
Wellington Shields Capital Management
New York
-$50.1K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$36.7K
4
WSC
Wellington Shields & Co
New York
-$11.6K
5
TRCT
Tower Research Capital (TRC)
New York
-$3.5K

CASI Hedge Fund Activity: Q1 2023 in Review

21 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q1 2023, worth a combined $2.15M — down 35% from $3.29M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of CASI and 1 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 4 added.

The largest buyer was UBS Group, adding an estimated $9.15K. The largest seller was Federated Hermes, exiting entirely with an estimated $1.58M sold.

  • 21 institutional investors held CASI Pharmaceuticals (CASI) as of Q1 2023, down from 23 in Q4 2022.
  • Funds reported $2.15M of CASI Pharmaceuticals stock for Q1 2023, down 35% quarter-over-quarter.
  • 1 fund opened new CASI Pharmaceuticals positions in Q1 2023 and 3 closed out, a net change of -2 holders.
  • The largest CASI Pharmaceuticals buyer in Q1 2023 was UBS Group, an estimated $9.15K added.
  • The largest CASI Pharmaceuticals seller in Q1 2023 was Federated Hermes, an estimated $1.58M sold.

Based on aggregated 13F filings for Q1 2023.